Moreover, in a recent study, Wang et al. co-delivered TMZ with an EGFR-siRNA in polymeric nanoparticles and observed that while in mice treated with TMZ, tumors grew rapidly with a glioma inhibition rate of 164.3, the tumor inhibition rate for animals treated with both drugs was 15.3, suggesting a high antitumor efficacy and synergic effect 77. This evidence concerns the gene EGFR and central nervous system cancer.